Cover Letter Journal Paper Submission Corp

Three Cover Letter Templates to Journal Editors
Each cover letter is unique, and those addressed to journal editors by scientists and academics when they submit their writing for publication are no exception. As an opportunity to present original research in the best possible light, a cover letter is indispensible for persuading a busy editor that a manuscript is worthy of peer review. A letter can only achieve this goal, however, if it is well written, contains everything the particular journal’s author instructions request for cover letters and offers specific and detailed information about why the research reported and the paper itself are perfect for the journal and of special interest to its readers. The originality that should characterise an excellent cover letter therefore prevents the wholesale use of a universal template without significant alterations, but the three sample letters that appear below may prove helpful for scholars who are planning, formatting and drafting a professional cover letter to a journal editor.

The content of the three sample letters is entirely fictional, with the dates, names, titles and situations invented. The specifics pertinent to your own research, your manuscript and the journal you are targeting will give you the raw material to emulate these templates. The format of a traditional business letter has been observed, so contact information for the authors and editors has been provided as complete mailing addresses. This formality may not be strictly necessary when communicating with a journal editor via email, where such details are often truncated, but the complete forms are always acceptable, and proper names and titles are a necessity. If possible, the official letterhead of the university, department or other research body with which you are affiliated should be used along with your name, phone number and professional email address.

Descriptions of the research and manuscript in each of the three examples have been kept simple so that the meaning will be clear to readers of all specialisations, but there are certainly successful cover letters that delve into a good deal more detail. Letter 2 below, for instance, might productively say more about the specific lights used and tomato plants grown and provide numbers and percentages as well. Do keep in mind, however, that the clarity and accessibility offered by a short and simple approach is also valuable, particularly when writing to an editor who may not share your precise specialisation.

Letter 1 adopts the perspective of a doctoral candidate who has rewritten the literature review chapter of his thesis as a bibliographical study and is seeking publication for the first time. Letter 2 introduces a research paper written by several authors and demonstrates how to act as the corresponding author when submitting a multi-author manuscript. Letter 3 posits that the author met the journal editor at a recent conference where an earlier version of the paper now being submitted for a theme issue of the journal was presented.

Letter 1: A Doctoral Candidate Seeking His First Publication

Joe Student
Department of English
University of the Western Shore
San Francisco, CA, USA 98765

Dr. Brian Editing
Journal of Analytical Middle English Bibliography
New York, NY, USA 12345

November 8, 2017

Dear Dr. Editing,

I am writing to submit my article entitled ‘A Bibliography of Hoccleve Studies from the Fifteenth Century to 2017: Patterns of Readership and Response’ for publication in the Journal of Analytical Middle English Bibliography. This manuscript is based on a chapter of my doctoral thesis, supervised by Dr Hoccleve Specialist, and has not been published or submitted elsewhere for consideration.

I believe this manuscript is appropriate for the Journal of Analytical Middle English Bibliography because it combines a complete list and critical summary of previous studies with an in-depth analysis of not only individual contributions, but also the larger patterns of scholarship and their possible significance through the centuries. As I argue in the paper, the autobiographical nature of Hoccleve’s writing and the bouts of madness he claims to have experienced are topics upon which perspectives and approaches swing on a particularly long pendulum. Shifts in opinion regarding the literary quality of Hoccleve’s poetry are similarly striking. Current trends and the annotated Hoccleve bibliography will likely prove of special interest to many of your readers, enabling future research and encouraging scholarly self-awareness.

If you decide to consider the manuscript for publication, I suggest the following two experts as qualified reviewers:

Dr. Medieval Scholarship
Professor of English, Southern University

Dr. Manuscript Expert
Director of Medieval Studies, Northern University

Many thanks for your time and consideration. I look forward to your response.


Joe Student

Joe Student
Ph.D. Candidate and Teaching Assistant
Department of English
University of the Western Shore

Letter 2: A Corresponding Author Submitting an Article Written by Several Researchers

Jane Researcher
Private Plant Research Institute
9201 Pink Greenhouse Place
Coquitlam, BC, Canada, V0V 1A1

Dr Samuel Botanist
Managing Editor
Growing Our Greenhouse: A Journal of Current Research
2020 Glass Hill
Colorado Springs, CO, USA, 59678

November 22, 2017

Dear Dr Botanist,

I am delighted to submit an original research article entitled ‘LED Lights Increase Vitamin C Content in Greenhouse Cherry Tomatoes’ for publication in Growing Our Greenhouse: A Journal of Current Research. My colleagues and I at the Private Plant Research Institute in Coquitlam conducted the research and coauthored the manuscript; a full list of the names and affiliations of all ten coauthors is attached. We have all approved the manuscript for submission to Growing Our Greenhouse, and I have been chosen as the corresponding author.

The article is particularly appropriate for the journal’s section dedicated to the cultivation of fruits and vegetables. It is, in fact, a continuation of the research presented in our article ‘Can LED Lights Really Replace the Sun for Tomatoes?’ which was published in that section of Growing Our Greenhouse two years ago. Then we were analysing the results of our first two seasons of growing tomatoes under LED lights. One of the unexpected discoveries we made as we determined which plants and lights produced the best results was that vitamin C content appeared to increase when the ripening fruit was exposed to LED light.

The research reported in the manuscript I am submitting today was designed to investigate further the apparent increases in vitamin C. Its methodology is similar to that of our earlier study, but we used only those cherry tomato plants that we had already shown could thrive under LED lights. We also established a larger number of experimental groups to explore the effects of variables such as light colour, light intensity, hours of exposure, ambient temperature and presence or absence of sunlight. Our findings were convincing to say the least, with vitamin C content doubling and sometimes trebling in fruit exposed to additional LED light. Even fruit given only LED lighting and deprived of all natural sunlight far exceeded the vitamin C content of those tomatoes exposed to natural sunlight alone.

We trust that your readers will find our hands-on empirical method as effective as they have in the past and benefit from our practices and discoveries as they grow and experiment in their own greenhouses.

Thank you for your continuing interest and consideration.

Yours sincerely,

Jane Researcher

Jane Researcher
Research Director, Private Plant Research Institute

Letter 3: A Conference Participant Submitting a Paper to the Journal Editor She Met

Sheila Presenter
Chair, School of Business Management
Yorkshire University
2121 University Road
York, North Yorkshire, UK, YO33 7EE
01904 323232

Dr Margaret Publisher
Journal of Innovative Business Studies
178B West Central Avenue
London, UK, EC9M 6BB

25 November 2017

Dear Dr Publisher,

It was a pleasure meeting you and discussing our similar interests at the Business Management conference in London a couple of weeks ago. As promised, I have revised my presentation and am submitting it for your consideration for the upcoming issue of the Journal of Innovative Business Studies dedicated to management innovations. The new title of the manuscript is ‘Empathy as a Management Strategy Yields Significant Increases in Efficiency and Productivity.’

You might recall that we discussed the challenges of reshaping my presentation, which was designed to generate in conference attendees the emotional responses it discusses, to conform to the structural requirements of the Journal of Innovative Business Studies. The journal’s author instructions were actually very helpful, and I believe the overall argument of the paper is now clearer as a result of the rearrangement. I also took a look at the recent Journal of Innovative Business Studies articles by Sally Scholar and John Researcher that you recommended. The former was particularly helpful and I have cited it more than once in my closing discussion. That discussion has benefited significantly from our long talk at the conference and I hope you do not object to my acknowledgement of your insight.

As you know, the research presented in the manuscript is original and has not been published or submitted elsewhere. My methods comply with the journal’s ethical standards, I have no conflicts of interest to disclose and I have removed all traces of my identity in preparation for blind review. I would respectfully request that Stephen Harsh not review the manuscript, however. His knowledge in this area is extensive, but you may remember from his comments at the conference that he does not share my approach to management or view my recent research with a positive eye. I believe the following two experts would serve as more appropriate reviewers of my paper:

Frederick Newapproach
CEO, Management Innovations UK Inc.
Samantha Kindheart
Chair, Department of Business Management
University of the Wolds

I look forward to seeing you at the upcoming conference in Leeds. In the meantime, let me take this opportunity to thank you for your interest and consideration.

Best regards,

Sheila Presenter

Sheila Presenter
Chair, School of Business Management
Yorkshire University

Why Our Editing and Proofreading Services?
At we pride ourselves on our large and extremely dedicated team of academic and scientific professionals. Our proofreaders and editors are highly educated native speakers of English and their areas of specialisation range so widely that we are able to help our clients improve and perfect all kinds of research manuscripts for successful publication. Many members of our team work predominantly on articles intended for publication in scholarly journals, ensuring that formatting and references conform to author guidelines with precision and correcting grammar, punctuation, spelling and simple typing errors so that our customers are able to report their research in the clear and accurate ways required to impress acquisitions editors and earn publication.

Our editing services for authors of scientific papers and books are especially popular, but we have the experience and expertise to proofread and edit books in every scholarly discipline as well as beyond them, and some of our carefully trained proofreaders and editors work exclusively on helping students improve the formatting and language of their theses and dissertations. Whether you are preparing a conference paper for presentation or publication, polishing a professional report to share with your colleagues, or tackling the daunting task of editing and perfecting any kind of academic or scientific document, a qualified member of our expert team can provide invaluable assistance and give you greater confidence in your written work. Our translation services for scientific and academic documents have also proven immensely helpful for many of our international clients.

Related Posts

Submission Guidelines

Style and Format

File format

Manuscript files can be in the following formats: DOC, DOCX, or RTF. Microsoft Word documents should not be locked or protected. 

LaTeX manuscripts must be submitted as PDFs. Read the LaTeX guidelines.


Manuscripts can be any length. There are no restrictions on word count, number of figures, or amount of supporting information.

We encourage you to present and discuss your findings concisely.


Use a standard font size and any standard font, except for the font named “Symbol”. To add symbols to the manuscript, use the Insert → Symbol function in your word processor or paste in the appropriate Unicode character.


Limit manuscript sections and sub-sections to 3 heading levels. Make sure heading levels are clearly indicated in the manuscript text.

Layout and spacing

Manuscript text should be double-spaced.

Do not format text in multiple columns.

Page and line numbers

Include page numbers and line numbers in the manuscript file. Use continuous line numbers (do not restart the numbering on each page).


Footnotes are not permitted. If your manuscript contains footnotes, move the information into the main text or the reference list, depending on the content.


Manuscripts must be submitted in English. 

You may submit translations of the manuscript or abstract as supporting information. Read the supporting information guidelines.


Define abbreviations upon first appearance in the text.

Do not use non-standard abbreviations unless they appear at least three times in the text.

Keep abbreviations to a minimum.

Reference style

PLOS uses “Vancouver” style, as outlined in the ICMJE sample references.

See reference formatting examples and additional instructions below.


We recommend using MathType for display and inline equations, as it will provide the most reliable outcome. If this is not possible, Equation Editor or Microsoft's Insert→Equation function is acceptable.

Avoid using MathType, Equation Editor, or the Insert→Equation function to insert single variables (e.g., “a² + b² = c²”), Greek or other symbols (e.g., β, Δ, or ′ [prime]), or mathematical operators (e.g., x, ≥, or  ±) in running text. Wherever possible, insert single symbols as normal text with the correct Unicode (hex) values.

Do not use MathType, Equation Editor, or the Insert→Equation function for only a portion of an equation. Rather, ensure that the entire equation is included. Equations should not contain a mix of different equation tools. Avoid “hybrid” inline or display equations, in which part is text and part is MathType, or part is MathType and part is Equation Editor.


 Use correct and established nomenclature wherever possible.

Units of measurementUse SI units. If you do not use these exclusively, provide the SI value in parentheses after each value. Read more about SI units.
DrugsProvide the Recommended International Non-Proprietary Name (rINN).
Species namesWrite in italics (e.g., Homo sapiens). Write out in full the genus and species, both in the title of the manuscript and at the first mention of an organism in a paper. After first mention, the first letter of the genus name followed by the full species name may be used (e.g., H. sapiens).
Genes, mutations, genotypes, and allelesWrite in italics. Use the recommended name by consulting the appropriate genetic nomenclature database (e.g., HUGO for human genes). It is sometimes advisable to indicate the synonyms for the gene the first time it appears in the text. Gene prefixes such as those used for oncogenes or cellular localization should be shown in roman typeface (e.g., v-fes, c-MYC).

The systematic allergen nomenclature of the World Health Organization/International Union of Immunological Societies (WHO/IUIS) Allergen Nomenclature Sub-committee should be used for manuscripts that include the description or use of allergenic proteins. For manuscripts describing new allergens, the systematic name of the allergen should be approved by the WHO/IUIS Allergen Nomenclature Sub-Committee prior to manuscript publication. Examples of the systematic allergen nomenclature can be found at the WHO/IUIS Allergen Nomenclature site.

Copyediting manuscripts

Prior to submission, authors who believe their manuscripts would benefit from professional editing are encouraged to use language-editing and copyediting services. Obtaining this service is the responsibility of the author, and should be done before initial submission. These services can be found on the web using search terms like “scientific editing service” or “manuscript editing service.”

Submissions are not copyedited before publication.

Submissions that do not meet the  PLOS ONE publication criterion for language standards may be rejected.

Manuscript Organization

Manuscripts should be organized as follows. Instructions for each element appear below the list.

Beginning section

The following elements are required, in order:

  • Title page: List title, authors, and affiliations as first page of manuscript
  • Abstract
  • Introduction
Middle section

The following elements can be renamed as needed and presented in any order:

  • Materials and Methods
  • Results
  • Discussion
  • Conclusions (optional)
Ending section

The following elements are required, in order:

  • Acknowledgments
  • References
  • Supporting information captions (if applicable)
Other elements
  • Figure captions are inserted immediately after the first paragraph in which the figure is cited. Figure files are uploaded separately.
  • Tables are inserted immediately after the first paragraph in which they are cited.
  • Supporting information files are uploaded separately.


Viewing Figures and Supporting Information in the compiled submission PDF
The compiled submission PDF includes low-resolution preview images of the figures after the reference list. The function of these previews is to allow you to download the entire submission as quickly as possible. Click the link at the top of each preview page to download a high-resolution version of each figure. Links to download Supporting Information files are also available after the reference list.

Parts of a Submission


Include a full title and a short title for the manuscript.

Full title250 charactersSpecific, descriptive, concise, and comprehensible to readers outside the field

Impact of cigarette smoke exposure on innate immunity: A Caenorhabditis elegans model

Solar drinking water disinfection (SODIS) to reduce childhood diarrhoea in rural Bolivia: A cluster-randomized, controlled trial

Short title100 charactersState the topic of the study

Cigarette smoke exposure and innate immunity

SODIS and childhood diarrhoea

Titles should be written in sentence case (only the first word of the text, proper nouns, and genus names are capitalized). Avoid specialist abbreviations if possible. For clinical trials, systematic reviews, or meta-analyses, the subtitle should include the study design.

Author list

Authorship requirements

All authors must meet the criteria for authorship as outlined in the  authorship policy. Those who contributed to the work but do not meet the criteria for authorship can be mentioned in the Acknowledgments.  Read more about Acknowledgments.

The corresponding author must provide an ORCID iD at the time of submission by entering it in the user profile in the submission system.  Read more about ORCID.

Author names and affiliations

Enter author names on the title page of the manuscript and in the online submission system.

On the title page, write author names in the following order:

  • First name (or initials, if used)
  • Middle name (or initials, if used)
  • Last name (surname, family name)

Each author on the list must have an affiliation. The affiliation includes department, university, or organizational affiliation and its location, including city, state/province (if applicable), and country. Authors have the option to include a current address in addition to the address of their affiliation at the time of the study. The current address should be listed in the byline and clearly labeled “current address.” At a minimum, the address must include the author’s current institution, city, and country.

If an author has multiple affiliations, enter all affiliations on the title page only. In the submission system, enter only the preferred or primary affiliation. Author affiliations will be listed in the typeset PDF article in the same order that authors are listed in the submission.

Author names will be published exactly as they appear in the manuscript file. Please double-check the information carefully to make sure it is correct.

Corresponding author

The submitting author is automatically designated as the corresponding author in the submission system. The corresponding author is the primary contact for the journal office and the only author able to view or change the manuscript while it is under editorial consideration.

The corresponding author role may be transferred to another coauthor. However, note that transferring the corresponding author role also transfers access to the manuscript. (To designate a new corresponding author while the manuscript is still under consideration, watch the video tutorial below.)

Only one corresponding author can be designated in the submission system, but this does not restrict the number of corresponding authors that may be listed on the article in the event of publication. Whoever is designated as a corresponding author on the title page of the manuscript file will be listed as such upon publication. Include an email address for each corresponding author listed on the title page of the manuscript.

  How to select a new corresponding author in Editorial Manager

Consortia and group authorship

If a manuscript is submitted on behalf of a consortium or group, include the consortium or group name in the author list, and provide the full list of consortium or group members in the Acknowledgments section. The consortium or group name should be listed in the manuscript file only, and not included in the online submission form. Please be aware that as of October 2016, the National Library of Medicine’s (NLM) policy has changed and PubMed will only index individuals and the names of consortia or group authors listed in the author byline itself. Individual consortium or group author members need to be listed in the author byline in order to be indexed, and if included in the byline, must qualify for authorship according to our criteria.

Read about the group authorship policy.

Author contributions

Provide at minimum one contribution for each author in the submission system. Use the CRediT taxonomy to describe each contribution. Read the policy and the full list of roles.

Contributions will be published with the final article, and they should accurately reflect contributions to the work. The submitting author is responsible for completing this information at submission, and we expect that all authors will have reviewed, discussed, and agreed to their individual contributions ahead of this time.

PLOS ONE will contact all authors by email at submission to ensure that they are aware of the submission.

Cover letter

Upload a cover letter as a separate file in the online system. The length limit is 1 page.

The cover letter should include the following information:

  • Summarize the study’s contribution to the scientific literature
  • Relate the study to previously published work
  • Specify the type of article (for example, research article, systematic review, meta-analysis, clinical trial)
  • Describe any prior interactions with PLOS regarding the submitted manuscript
  • Suggest appropriate Academic Editors to handle your manuscript (see the full list of Academic Editors)
  • List any opposed reviewers

IMPORTANT: Do not include requests to reduce or waive publication fees in the cover letter. This information will be entered separately in the online submission system.

Read about publication fee assistance.

Title page

The title, authors, and affiliations should all be included on a title page as the first page of the manuscript file.  


The Abstract comes after the title page in the manuscript file. The abstract text is also entered in a separate field in the submission system.  

The Abstract should:

  • Describe the main objective(s) of the study
  • Explain how the study was done, including any model organisms used, without methodological detail
  • Summarize the most important results and their significance
  • Not exceed 300 words

Abstracts should not include:

  • Citations
  • Abbreviations, if possible


The introduction should:

  • Provide background that puts the manuscript into context and allows readers outside the field to understand the purpose and significance of the study
  • Define the problem addressed and why it is important
  • Include a brief review of the key literature
  • Note any relevant controversies or disagreements in the field
  • Conclude with a brief statement of the overall aim of the work and a comment about whether that aim was achieved

Materials and Methods

The Materials and Methods section should provide enough detail to allow suitably skilled investigators to fully replicate your study. Specific information and/or protocols for new methods should be included in detail. If materials, methods, and protocols are well established, authors may cite articles where those protocols are described in detail, but the submission should include sufficient information to be understood independent of these references.

Protocol documents for clinical trials, observational studies, and other non-laboratory investigations may be uploaded as supporting information. Read the supporting information guidelines for formatting instructions. We recommend depositing laboratory protocols at Read detailed instructions for depositing and sharing your laboratory protocols.

Human or animal subjects and/or tissue or field sampling

Methods sections describing research using human or animal subjects and/or tissue or field sampling must include required ethics statements. See the reporting guidelines for human research, clinical trials, animal research, and observational and field studies for more information.


PLOS journals require authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception.

Large data sets, including raw data, may be deposited in an appropriate public repository. See our list of recommended repositories.

For smaller data sets and certain data types, authors may provide their data within supporting information files accompanying the manuscript. Authors should take care to maximize the accessibility and reusability of the data by selecting a file format from which data can be efficiently extracted (for example, spreadsheets or flat files should be provided rather than PDFs when providing tabulated data).

For more information on how best to provide data, read our policy on data availability. PLOS does not accept references to “data not shown.”

Cell lines

Methods sections describing research using cell lines must state the origin of the cell lines used. See the reporting guidelines for cell line research for more information.

Laboratory Protocols

To enhance the reproducibility of your results, we recommend and encourage you to deposit laboratory protocols in, where protocols can be assigned their own persistent digital object identifiers (DOIs).

To include a link to a protocol in your article:

  1. Describe your step-by-step protocol on
  2. Select Get DOI to issue your protocol a persistent digital object identifier (DOI) 
  3. Include the DOI link in the Methods section of your manuscript using the following format provided by[PROTOCOL DOI]

At this stage, your protocol is only visible to those with the link. This allows editors and reviewers to consult your protocol when evaluating the manuscript. You can make your protocols public at any time by selecting Publish on the site. Any referenced protocol(s) will automatically be made public when your article is published.

New taxon names

Methods sections of manuscripts adding new taxon names to the literature must follow the reporting guidelines below for a new zoological taxon, botanical taxon, or fungal taxon.

Results, Discussion, Conclusions

These sections may all be separate, or may be combined to create a mixed Results/Discussion section (commonly labeled “Results and Discussion”) or a mixed Discussion/Conclusions section (commonly labeled “Discussion”). These sections may be further divided into subsections, each with a concise subheading, as appropriate. These sections have no word limit, but the language should be clear and concise.

Together, these sections should describe the results of the experiments, the interpretation of these results, and the conclusions that can be drawn.

Authors should explain how the results relate to the hypothesis presented as the basis of the study and provide a succinct explanation of the implications of the findings, particularly in relation to previous related studies and potential future directions for research.

PLOS ONE editorial decisions do not rely on perceived significance or impact, so authors should avoid overstating their conclusions. See the PLOS ONE Criteria for Publication for more information.


Those who contributed to the work but do not meet our authorship criteria should be listed in the Acknowledgments with a description of the contribution.

Authors are responsible for ensuring that anyone named in the Acknowledgments agrees to be named.

Do not include funding sources in the Acknowledgments or anywhere else in the manuscript file. Funding information should only be entered in the financial disclosure section of the submission system.


Any and all available works can be cited in the reference list. Acceptable sources include:

  • Published or accepted manuscripts
  • Manuscripts on preprint servers, providing the manuscript has a citable DOI or arXiv URL. Read the Preprint Policy.

Do not cite the following sources in the reference list:

  • Unavailable and unpublished work, including manuscripts that have been submitted but not yet accepted (e.g., “unpublished work,” “data not shown”). Instead, include those data as supplementary material or deposit the data in a publicly available database.
  • Personal communications (these should be supported by a letter from the relevant authors but not included in the reference list)

References are listed at the end of the manuscript and numbered in the order that they appear in the text. In the text, cite the reference number in square brackets (e.g., “We used the techniques developed by our colleagues [19] to analyze the data”). PLOS uses the numbered citation (citation-sequence) method and first six authors, et al.

Do not include citations in abstracts or author summaries. 

Make sure the parts of the manuscript are in the correct order before ordering the citations.

Formatting references

Because all references will be linked electronically as much as possible to the papers they cite, proper formatting of the references is crucial. 

PLOS uses the reference style outlined by the International Committee of Medical Journal Editors (ICMJE), also referred to as the “Vancouver” style. Example formats are listed below. Additional examples are in the ICMJE sample references.

A reference management tool, EndNote, offers a current style file that can assist you with the formatting of your references. If you have problems with any reference management program, please contact the source company's technical support.

Journal name abbreviations should be those found in the National Center for Biotechnology Information (NCBI) databases. 

Published articles

Hou WR, Hou YL, Wu GF, Song Y, Su XL, Sun B, et al. cDNA, genomic sequence cloning and overexpression of ribosomal protein gene L9 (rpL9) of the giant panda (Ailuropoda melanoleuca). Genet Mol Res. 2011;10: 1576-1588.

Devaraju P, Gulati R, Antony PT, Mithun CB, Negi VS. Susceptibility to SLE in South Indian Tamils may be influenced by genetic selection pressure on TLR2 and TLR9 genes. Mol Immunol. 2014 Nov 22. pii: S0161-5890(14)00313-7. doi: 10.1016/j.molimm.2014.11.005.

Note: A DOI number for the full-text article is acceptable as an alternative to or in addition to traditional volume and page numbers. When providing a DOI, adhere to the format in the example above with both the label and full DOI included at the end of the reference (doi: 10.1016/j.molimm.2014.11.005). Do not provide a shortened DOI or the URL.
Accepted, unpublished articlesSame as published articles, but substitute “Forthcoming” for page numbers or DOI.
Online articles

Huynen MMTE, Martens P, Hilderlink HBM. The health impacts of globalisation: a conceptual framework. Global Health. 2005;1: 14. Available from:


Bates B. Bargaining for life: A social history of tuberculosis. 1st ed. Philadelphia: University of Pennsylvania Press; 1992.

Book chaptersHansen B. New York City epidemics and history for the public. In: Harden VA, Risse GB, editors. AIDS and the historian. Bethesda: National Institutes of Health; 1991. pp. 21-28.
Deposited articles (preprints, e-prints, or arXiv)Krick T, Shub DA, Verstraete N, Ferreiro DU, Alonso LG, Shub M, et al. Amino acid metabolism conflicts with protein diversity; 1991. Preprint. Available from: arXiv:1403.3301v1. Cited 17 March 2014.
Published media (print or online newspapers and magazine articles)Fountain H. For Already Vulnerable Penguins, Study Finds Climate Change Is Another Danger. The New York Times. 29 Jan 2014. Available from: Cited 17 March 2014.
New media (blogs, web sites, or other written works)Allen L. Announcing PLOS Blogs. 2010 Sep 1 [cited 17 March 2014]. In: PLOS Blogs [Internet]. San Francisco: PLOS 2006 - . [about 2 screens]. Available from:
Masters' theses or doctoral dissertationsWells A. Exploring the development of the independent, electronic, scholarly journal. M.Sc. Thesis, The University of Sheffield. 1999. Available from:
Databases and repositories (Figshare, arXiv)Roberts SB. QPX Genome Browser Feature Tracks; 2013 [cited 2013 Oct 5]. Database: figshare [Internet]. Available from:
Multimedia (videos, movies, or TV shows)Hitchcock A, producer and director. Rear Window [Film]; 1954. Los Angeles: MGM.

Supporting Information

Authors can submit essential supporting files and multimedia files along with their manuscripts. All supporting information will be subject to peer review. All file types can be submitted, but files must be smaller than 10 MB in size.

Authors may use almost any description as the item name for a supporting information file as long as it contains an “S” and number. For example, “S1 Appendix” and “S2 Appendix,” “S1 Table” and “S2 Table,” and so forth.  

Supporting information files are published exactly as provided, and are not copyedited.

Supporting information captions

List supporting information captions at the end of the manuscript file. Do not submit captions in a separate file.

The file number and name are required in a caption, and we highly recommend including a one-line title as well. You may also include a legend in your caption, but it is not required.

Example caption

S1 Text. Title is strongly recommended.
 Legend is optional.

In-text citations

We recommend that you cite supporting information in the manuscript text, but this is not a requirement. If you cite supporting information in the text, citations do not need to be in numerical order.

Read the supporting information guidelines for more details about submitting supporting information and multimedia files.

Figures and Tables


Do not include figures in the main manuscript file. Each figure must be prepared and submitted as an individual file.

Cite figures in ascending numeric order upon first appearance in the manuscript file.

Read the guidelines for figures.

Figure captions

Figure captions must be inserted in the text of the manuscript, immediately following the paragraph in which the figure is first cited (read order). Do not include captions as part of the figure files themselves or submit them in a separate document.

At a minimum, include the following in your figure captions:

  • A figure label with Arabic numerals, and “Figure” abbreviated to “Fig” (e.g. Fig 1, Fig 2, Fig 3, etc). Match the label of your figure with the name of the file uploaded at submission (e.g. a figure citation of “Fig 1” must refer to a figure file named “Fig1.tif”).
  • A concise, descriptive title

The caption may also include a legend as needed.

Read more about figure captions.


Cite tables in ascending numeric order upon first appearance in the manuscript file.

Place each table in your manuscript file directly after the paragraph in which it is first cited (read order). Do not submit your tables in separate files.

Tables require a label (e.g., “Table 1”) and brief descriptive title to be placed above the table. Place legends, footnotes, and other text below the table. 

Read the guidelines for tables.

Data reporting

All data and related metadata underlying the findings reported in a submitted manuscript should be deposited in an appropriate public repository, unless already provided as part of the submitted article.

Read our policy on data availability.

Repositories may be either subject-specific (where these exist) and accept specific types of structured data, or generalist repositories that accept multiple data types. We recommend that authors select repositories appropriate to their field. Repositories may be subject-specific (e.g., GenBank for sequences and PDB for structures), general, or institutional, as long as DOIs or accession numbers are provided and the data are at least as open as CC BY. Authors are encouraged to select repositories that meet accepted criteria as trustworthy digital repositories, such as criteria of the Centre for Research Libraries or Data Seal of Approval. Large, international databases are more likely to persist than small, local ones.

See our list of recommended repositories.

To support data sharing and author compliance of the PLOS data policy, we have integrated our submission process with a select set of data repositories. The list is neither representative nor exhaustive of the suitable repositories available to authors. Current repository integration partners include Dryad and FlowRepository. Please contact to make recommendations for further partnerships.

Instructions for PLOS submissions with data deposited in an integration partner repository:

  • Deposit data in the integrated repository of choice.
  • Once deposition is final and complete, the repository will provide you with a dataset DOI (provisional) and private URL for reviewers to gain access to the data.
  • Enter the given data DOI into the full Data Availability Statement, which is requested in the Additional Information section of the PLOS submission form. Then provide the URL passcode in the Attach Files section.

If you have any questions, please email us.

Accession numbers

All appropriate data sets, images, and information should be deposited in an appropriate public repository. See our list of recommended repositories.

Accession numbers (and version numbers, if appropriate) should be provided in the Data Availability Statement. Accession numbers or a citation to the DOI should also be provided when the data set is mentioned within the manuscript.

In some cases authors may not be able to obtain accession numbers of DOIs until the manuscript is accepted; in these cases, the authors must provide these numbers at acceptance. In all other cases, these numbers must be provided at submission.


As much as possible, please provide accession numbers or identifiers for all entities such as genes, proteins, mutants, diseases, etc., for which there is an entry in a public database, for example:

Identifiers should be provided in parentheses after the entity on first use.

Striking image

You can choose to upload a “Striking Image” that we may use to represent your article online in places like the journal homepage or in search results.

The striking image must be derived from a figure or supporting information file from the submission, i.e., a cropped portion of an image or the entire image. Striking images should ideally be high resolution, eye-catching, single panel images, and should ideally avoid containing added details such as text, scale bars, and arrows.

If no striking image is uploaded, we will designate a figure from the submission as the striking image.

Additional Information Requested at Submission

Funding Statement

This information should not be in your manuscript file; you will provide it via our submission system.

This information will be published with the final manuscript, if accepted, so please make sure that this is accurate and as detailed as possible. You should not include this information in your manuscript file, but it is important to gather it prior to submission, because your financial disclosure statement cannot be changed after initial submission.

Your statement should include relevant grant numbers and the URL of any funder's web site. Please also state whether any individuals employed or contracted by the funders (other than the named authors) played any role in: study design, data collection and analysis, decision to publish, or preparation of the manuscript. If so, please name the individual and describe their role.

Read our policy on disclosure of funding sources.

Competing Interests

This information should not be in your manuscript file; you will provide it via our submission system.

All potential competing interests must be declared in full. If the submission is related to any patents, patent applications, or products in development or for market, these details, including patent numbers and titles, must be disclosed in full.

Read our policy on competing interests.

Manuscripts disputing published work

For manuscripts disputing previously published work, it is PLOS ONE policy to invite a signed review by the disputed author during the peer review process. This procedure is aimed at ensuring a thorough, transparent, and productive review process.

If the disputed author chooses to submit a review, it must be returned in a timely fashion and contain a full declaration of all competing interests. The Academic Editor will consider any such reviews in light of the competing interest.

Authors submitting manuscripts disputing previous work should explain the relationship between the manuscripts in their cover letter, and will be required to confirm that they accept the conditions of this review policy before the manuscript is considered further.

Related manuscripts

Upon submission, authors must confirm that the manuscript, or any related manuscript, is not currently under consideration or accepted elsewhere. If related work has been submitted to PLOS ONE or elsewhere, authors must include a copy with the submitted article. Reviewers will be asked to comment on the overlap between related submissions.

We strongly discourage the unnecessary division of related work into separate manuscripts, and we will not consider manuscripts that are divided into “parts.” Each submission to PLOS ONE must be written as an independent unit and should not rely on any work that has not already been accepted for publication. If related manuscripts are submitted to PLOS ONE, the authors may be advised to combine them into a single manuscript at the editor's discretion.

PLOS does support authors who wish to share their work early and receive feedback before formal peer review. Deposition of manuscripts with preprint servers does not impact consideration of the manuscript at any PLOS journal.

Guidelines for Specific Study Types

Human subjects research

All research involving human participants must have been approved by the authors’ Institutional Review Board (IRB) or by equivalent ethics committee(s), and must have been conducted according to the principles expressed in the Declaration of Helsinki. Authors should be able to submit, upon request, a statement from the IRB or ethics committee indicating approval of the research. We reserve the right to reject work that we believe has not been conducted to a high ethical standard, even when formal approval has been obtained.

Subjects must have been properly instructed and have indicated that they consent to participate by signing the appropriate informed consent paperwork. Authors may be asked to submit a blank, sample copy of a subject consent form. If consent was verbal instead of written, or if consent could not be obtained, the authors must explain the reason in the manuscript, and the use of verbal consent or the lack of consent must have been approved by the IRB or ethics committee.

All efforts should be made to protect patient privacy and anonymity. Identifying information, including photos, should not be included in the manuscript unless the information is crucial and the individual has provided written consent by completing the  Consent Form for Publication in a PLOS Journal (PDF). Download additional translations of the form from the Downloads and Translations page. More information about patient privacy, anonymity, and informed consent can be found in the International Committee of Medical Journal Editors (ICMJE) Privacy and Confidentiality guidelines.

Manuscripts should conform to the following reporting guidelines:

  • Studies of diagnostic accuracy: STARD
  • Observational studies: STROBE
  • Microarray experiments: MIAME
  • Other types of health-related research: Consult the EQUATOR web site for appropriate reporting guidelines

Methods sections of papers on research using human subjects or samples must include ethics statements that specify:

  • The name of the approving institutional review board or equivalent committee(s). If approval was not obtained, the authors must provide a detailed statement explaining why it was not needed
  • Whether informed consent was written or oral. If informed consent was oral, it must be stated in the manuscript:
    • Why written consent could not be obtained
    • That the Institutional Review Board (IRB) approved use of oral consent
    • How oral consent was documented

For studies involving humans categorized by race/ethnicity, age, disease/disabilities, religion, sex/gender, sexual orientation, or other socially constructed groupings, authors should:

  • Explicitly describe their methods of categorizing human populations
  • Define categories in as much detail as the study protocol allows
  • Justify their choices of definitions and categories, including for example whether any rules of human categorization were required by their funding agency
  • Explain whether (and if so, how) they controlled for confounding variables such as socioeconomic status, nutrition, environmental exposures, or similar factors in their analysis

In addition, outmoded terms and potentially stigmatizing labels should be changed to more current, acceptable terminology. Examples: “Caucasian” should be changed to “white” or “of [Western] European descent” (as appropriate); “cancer victims” should be changed to “patients with cancer.”

For papers that include identifying, or potentially identifying, information, authors must download the Consent Form for Publication in a PLOS Journal, which the individual, parent, or guardian must sign once they have read the paper and been informed about the terms of PLOS open-access license. The signed consent form should not be submitted with the manuscript, but authors should securely file it in the individual's case notes and the methods section of the manuscript should explicitly state that consent authorization for publication is on file, using wording like:

The individual in this manuscript has given written informed consent (as outlined in PLOS consent form) to publish these case details.

For more information about PLOS ONE policies regarding human subjects research, see the Publication Criteria and Editorial Policies.

Clinical trials

Clinical trials are subject to all policies regarding human research. PLOS ONE follows the World Health Organization's (WHO) definition of a clinical trial:

A clinical trial is any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes [...] Interventions include but are not restricted to drugs, cells and other biological products, surgical procedures, radiologic procedures, devices, behavioural treatments, process-of-care changes, preventive care, etc.

All clinical trials must be registered in one of the publicly-accessible registries approved by the WHO or ICMJE (International Committee of Medical Journal Editors). Authors must provide the trial registration number. Prior disclosure of results on a clinical trial registry site will not affect consideration for publication. We reserve the right to inform authors' institutions or ethics committees, and to reject the manuscript, if we become aware of unregistered trials.

PLOS ONE supports prospective trial registration (i.e. before participant recruitment has begun) as recommended by the ICMJE's clinical trial registration policy. Where trials were not publicly registered before participant recruitment began, authors must:

  • Register all related clinical trials and confirm they have done so in the Methods section
  • Explain in the Methods the reason for failing to register before participant recruitment

Clinical trials must be reported according to the relevant reporting guidelines, i.e. CONSORT for randomized controlled trials, TREND for non-randomized trials, and other specialized guidelines as appropriate. The intervention should be described according to the requirements of the TIDieR checklist and guide. Submissions must also include the study protocol as supporting information, which will be published with the manuscript if accepted.

Authors of manuscripts describing the results of clinical trials must adhere to the CONSORT reporting guidelines appropriate to their trial design, available on the CONSORT Statement web site. Before the paper can enter peer review, authors must:

  • Provide the registry name and number in the methods section of the manuscript
  • Provide a copy of the trial protocol as approved by the ethics committee and a completed CONSORT checklist as supporting information (which will be published alongside the paper, if accepted). This should be named S1 CONSORT Checklist.
  • Include the CONSORT flow diagram as the manuscript's “Fig 1”

Any deviation from the trial protocol must be explained in the paper. Authors must explicitly discuss informed consent in their paper, and we reserve the right to ask for a copy of the patient consent form.

The methods section must include the name of the registry, the registry number, and the URL of your trial in the registry database for each location in which the trial is registered.

Animal research

All research involving vertebrates or cephalopods must have approval from the authors' Institutional Animal Care and Use Committee (IACUC) or equivalent ethics committee(s), and must have been conducted according to applicable national and international guidelines. Approval must be received prior to beginning research.

Manuscripts reporting animal research must state in the Methods section:

  • The full name of the relevant ethics committee that approved the work, and the associated permit number(s).
  • Where ethical approval is not required, the manuscript should include a clear statement of this and the reason why. Provide any relevant regulations under which the study is exempt from the requirement for approval.
  • Relevant details of steps taken to ameliorate animal suffering.
Example ethics statement

This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was approved by the Committee on the Ethics of Animal Experiments of the University of Minnesota (Protocol Number: 27-2956). All surgery was performed under sodium pentobarbital anesthesia, and all efforts were made to minimize suffering.

Authors should always state the organism(s) studied in the Abstract. Where the study may be confused as pertaining to clinical research, authors should also state the animal model in the title.

To maximize reproducibility and potential for re-use of data, we encourage authors to follow the Animal Research: Reporting of In Vivo Experiments (ARRIVE) guidelines for all submissions describing laboratory-based animal research and to upload a completed ARRIVE Guidelines Checklist to be published as supporting information.

Non-human primates

Manuscripts describing research involving non-human primates must report details of husbandry and animal welfare in accordance with the recommendations of the Weatherall report, The use of non-human primates in research (PDF), including:

  • Information about housing, feeding, and environmental enrichment.
  • Steps taken to minimize suffering, including use of anesthesia and method of sacrifice, if appropriate.

Random source animals

Manuscripts describing studies that use random source (e.g. Class B dealer-sourced in the USA), shelter, or stray animals will be subject to additional scrutiny and may be rejected if sufficient ethical and scientific justification for the study design is lacking.

Unacceptable euthanasia methods and anesthetic agents

Manuscripts reporting use of a euthanasia method(s) classified as unacceptable by the American Veterinary Medical Association or use of an anesthesia method(s) that is widely prohibited (e.g., chloral hydrate, ether, chloroform) must include at the time of initial submission, scientific justification for use in the specific study design, as well as confirmation of approval for specific use from their animal research ethics committee. These manuscripts may be subject to additional ethics considerations prior to publication.

Humane endpoints

Manuscripts reporting studies in which death of a regulated animal (vertebrate, cephalopod) is a likely outcome or a planned experimental endpoint, must comprehensively report details of study design, rationale for the approach, and methodology, including consideration of humane endpoints. This applies to research that involves, for instance, assessment of survival, toxicity, longevity, terminal disease, or high rates of incidental mortality.

Definition of a humane endpoint

A humane endpoint is a predefined experimental endpoint at which animals are euthanized when they display early markers associated with death or poor prognosis of quality of life, or specific signs of severe suffering or distress. Humane endpoints are used as an alternative to allowing such conditions to continue or progress to death following the experimental intervention (“death as an endpoint”), or only euthanizing animals at the end of an experiment. Before a study begins, researchers define the practical observations or measurements that will be used during the study to recognize a humane endpoint, based on anticipated clinical, physiological, and behavioral signs. Please see the NC3Rs guidelines for more information. Additional discussion of humane endpoints can be found in this article:  Nuno H. Franco, Margarida Correia-Neves, I. Anna S. Olsson (2012) How “Humane” Is Your Endpoint? — Refining the Science-Driven Approach for Termination of Animal Studies of Chronic Infection. PLoS Pathog 8(1): e1002399

Full details of humane endpoints use must be reported for a study to be reproducible and for the results to be accurately interpreted.

For studies in which death of an animal is an outcome or a planned experimental endpoint, authors should include the following information in the Methods section of the manuscript:

  • The specific criteria (i.e. humane endpoints) used to determine when animals should be euthanized.
  • The duration of the experiment.
  • The numbers of animals used, euthanized, and found dead (if any); the cause of death for all animals.
  • How frequently animal health and behavior were monitored.
  • All animal welfare considerations taken, including efforts to minimize suffering and distress, use of analgesics or anaesthetics, or special housing conditions.

If humane endpoints were not used, the manuscript should report:

  • A scientific justification for the study design, including the reasons why humane endpoints could not be used, and discussion of alternatives that were considered.
  • Whether the institutional animal ethics committee specifically reviewed and approved the anticipated mortality in the study design.

Observational and field studies

Methods sections for submissions reporting on any type of field study must include ethics statements that specify:

  • Permits and approvals obtained for the work, including the full name of the authority that approved the study; if none were required, authors should explain why
  • Whether the land accessed is privately owned or protected
  • Whether any protected species were sampled
  • Full details of animal husbandry, experimentation, and care/welfare, where relevant

Paleontology and archaeology research

Manuscripts reporting paleontology and archaeology research must include descriptions of methods and specimens in sufficient detail to allow the work to be reproduced. Data sets supporting statistical and phylogenetic analyses should be provided, preferably in a format that allows easy re-use. Read the policy.

Specimen numbers and complete repository information, including museum name and geographic location, are required for publication. Locality information should be provided in the manuscript as legally allowable, or a statement should be included giving details of the availability of such information to qualified researchers.

If permits were required for any aspect of the work, details should be given of all permits that were obtained, including the full name of the issuing authority. This should be accompanied by the following statement:

All necessary permits were obtained for the described study, which complied with all relevant regulations.

If no permits were required, please include the following statement:

No permits were required for the described study, which complied with all relevant regulations.

Manuscripts describing paleontology and archaeology research are subject to the following policies:

  • Sharing of data and materials. Any specimen that is erected as a new species, described, or figured must be deposited in an accessible, permanent repository (i.e., public museum or similar institution). If study conclusions depend on specimens that do not fit these criteria, the article will be rejected under PLOS ONE's data availability criterion.
  • Ethics. PLOS ONE will not publish research on specimens that were obtained without necessary permission or were illegally exported.

Systematic reviews and meta-analyses

A systematic review paper, as defined by The Cochrane Collaboration, is a review of a clearly formulated question that uses explicit, systematic methods to identify, select, and critically appraise relevant research, and to collect and analyze data from the studies that are included in the review. These reviews differ substantially from narrative-based reviews or synthesis articles. Statistical methods (meta-analysis) may or may not be used to analyze and summarize the results of the included studies.

Reports of systematic reviews and meta-analyses must include a completed PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) checklist and flow diagram to accompany the main text. Blank templates are available here:

Authors must also state in their “Methods” section whether a protocol exists for their systematic review, and if so, provide a copy of the protocol as supporting information and provide the registry number in the abstract.

If your article is a systematic review or a meta-analysis you should:

  • State this in your cover letter
  • Select “Research Article” as your article type when submitting
  • Include the PRISMA flow diagram as Fig 1 (required where applicable)
  • Include the PRISMA checklist as supporting information

Meta-analysis of genetic association studies

Manuscripts reporting a meta-analysis of genetic association studies must report results of value to the field and should be reported according to the guidelines presented in Systematic Reviews of Genetic Association Studies by Sagoo et al.

On submission, authors will be asked to justify the rationale for the meta-analysis and how it contributes to the base of scientific knowledge in the light of previously published results. Authors will also be asked to complete a checklist (DOCX) outlining information about the justification for the study and the methodology employed. Meta-analyses that replicate published studies will be rejected if the authors do not provide adequate justification.

Personal data from third-party sources

For all studies using personal data from internet-based and other third-party sources (e.g., social media, blogs, other internet sources, mobile phone companies), data must be collected and used according to company/website Terms and Conditions, with appropriate permissions. All data sources must be acknowledged clearly in the Materials and Methods section.

Read our policy on data availability.    

In the Ethics Statement, authors should declare any potential risks to individuals or individual privacy, or affirm that in their assessment, the study posed no such risks. In addition, the following Ethics and Data Protection requirements must be met.

For interventional studies, which impact participants’ experiences or data, the study design must have been prospectively approved by an Ethics Committee, and informed consent is required. The Ethics Committee may waive the requirement for approval and/or consent.

For observational studies in which personal experiences and accounts are not manipulated, consultation with an Ethics or Data Protection Committee is recommended. Additional requirements apply in the following circumstances:

  • If information used could threaten personal privacy or damage the reputation of individuals whose data are used, an Ethics Committee should be consulted and informed consent obtained or specifically addressed.
  • If authors accessed any personal identifying information, an Ethics or Data Protection Committee should oversee data anonymization. If data were anonymized and/or aggregated before access and analysis, informed consent is generally not required.

Note that Terms of Use contracts do not qualify as informed consent, even if they address the use of personal data for research. 

See our reporting guidelines for human subjects research.

Cell lines

Authors reporting research using cell lines should state when and where they obtained the cells, giving the date and the name of the researcher, cell line repository, or commercial source (company) who provided the cells, as appropriate.

Authors must also include the following information for each cell line:

For de novo (new) cell lines, including those given to the researchers as a gift, authors must follow our policies for human subjects research or animal research, as appropriate. The ethics statement must include:

  • Details of institutional review board or ethics committee approval; AND
  • For human cells, confirmation of written informed consent from the donor, guardian, or next of kin

For established cell lines, the Methods section should include:

  • A reference to the published article that first described the cell line; AND/OR
  • The cell line repository or company the cell line was obtained from, the catalogue number, and whether the cell line was obtained directly from the repository/company or from another laboratory

Authors should check established cell lines using the ICLAC Database of Cross-contaminated or Misidentified Cell Lines to confirm they are not misidentified or contaminated. Cell line authentication is recommended – e.g., by karyotyping, isozyme analysis, or short tandem repeats (STR) analysis – and may be required during peer review or after publication.

Blots and gels

Manuscripts reporting results from blots (including Western blots) and electrophoretic gels should follow these guidelines:

  • In accordance with our policy on image manipulation, the image should not be adjusted in any way that could affect the scientific information displayed, e.g. by modifying the background or contrast. 
  • All blots and gels that support results reported in the manuscript should be provided.
  • Original uncropped and unadjusted blots and gels, including molecular size markers, should be provided in either the figures or the supplementary files.
  • Lanes should not be overcropped around the bands; the image should show most or all of the blot or gel. Any non-specific bands should be shown and an explanation of their nature should be given.
  • The image should include all relevant controls, and controls should be run on the same blot or gel as the samples.
  • A figure panel should not include composite images of bands originating from different blots or gels. If the figure shows non-adjacent bands from the same blot or gel, this should be clearly denoted by vertical black lines and the figure legend should provide details of how the figure was made.


Manuscripts reporting experiments using antibodies should include the following information:

  • The name of each antibody, a description of whether it is monoclonal or polyclonal, and the host species.
  • The commercial supplier or source laboratory.
  • The catalogue or clone number and, if known, the batch number.
  • The antigen(s) used to raise the antibody.
  • For established antibodies, a stable public identifier from the Antibody Registry.

The manuscript should also report the following experimental details:

  • The final antibody concentration or dilution.
  • A reference to the validation study if the antibody was previously validated. If not, provide details of how the authors validated the antibody for the applications and species used. 

Related information for authors

  Please refer to our downloadable sample files to ensure that your submission meets our formatting requirements:


Leave a Reply

Your email address will not be published. Required fields are marked *